Membrane Glycoproteins

Name
Membrane Glycoproteins
Accession Number
DBCAT002880
Description

Glycoproteins found on the membrane or surface of cells.

Drugs
DrugDrug Description
AdecatumumabInvestigated for use/treatment in breast cancer and prostate cancer.
Thrombomodulin AlfaInvestigated for use/treatment in blood preservative, blood (blood forming organ disorders, unspecified), sepsis and septicemia, and thrombosis.
Recombinant CD40-ligandRecombinant CD40-ligand is under investigation in clinical trial NCT00053391 (Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma).
FibronectinFibronectin is under investigation in clinical trial NCT01812239 (Vaginal Progesterone in Twins With Short Cervix).
Cystic fibrosis transmembrane conductance regulatorCystic fibrosis transmembrane conductance regulator is under investigation in clinical trial NCT00004806 (Phase I Study of Liposome-Mediated Gene Transfer in Patients With Cystic Fibrosis).
AlefaceptA recombinant fusion protein that binds CD2 and is used treat moderate to severe plaque psoriasis.
PRO-542Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications.
PegdinetanibInvestigated for use/treatment in cancer/tumors (unspecified) and macular degeneration.
GI-6207Not Annotated
EDI-200EDI-200 is a fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1.
Drugs & Drug Targets
DrugTargetType
Thrombomodulin AlfaCoagulation factor Vtarget
Thrombomodulin AlfaProthrombintarget
AlefaceptT-cell surface antigen CD2target
AlefaceptLow affinity immunoglobulin gamma Fc region receptor III-Btarget
AlefaceptLow affinity immunoglobulin gamma Fc region receptor III-Atarget
PRO-542Free fatty acid receptor 4target
PegdinetanibVascular endothelial growth factor receptor 2target